Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5287)
All Articles published online
|
Sep 21, 2012 (publication date) through Apr 16, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 2012; 18(35): 4944-4958 [PMID: 23002368 DOI: 10.3748/wjg.v18.i35.4944] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v18/i35/4944.htm |
| Number | Citing Articles |
| 1 |
Btissame El Hassouni, Giovanna Li Petri, Daniel S.K. Liu, Stella Cascioferro, Barbara Parrino, Waqar Hassan, Patrizia Diana, Asif Ali, Adam E Frampton, Elisa Giovannetti. Pharmacogenetics of treatments for pancreatic cancer. Expert Opinion on Drug Metabolism & Toxicology 2019; 15(6): 437 doi: 10.1080/17425255.2019.1620731
|
| 2 |
Tae Kim, Soyoung Shin, Sarah Kim, Jürgen Bulitta, Kwon-Yeon Weon, Sang Joo, Eunsook Ma, Sun Yoo, Gi-Young Park, Dong Kwon, Seok Jeong, Da Lee, Beom Shin. Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine. Molecules 2017; 22(9): 1515 doi: 10.3390/molecules22091515
|
| 3 |
Daniel Ansari, Bobby Tingstedt, Roland Andersson. Pancreatic cancer – cost for overtreatment with gemcitabine. Acta Oncologica 2013; 52(6): 1146 doi: 10.3109/0284186X.2012.744140
|
| 4 |
Chiara Caparello, Laura L Meijer, Ingrid Garajova, Alfredo Falcone, Tessa Y Le Large, Niccola Funel, Geert Kazemier, Godefridus J Peters, Enrico Vasile, Elisa Giovannetti. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World Journal of Gastroenterology 2016; 22(31): 6987-7005 doi: 10.3748/wjg.v22.i31.6987
|
| 5 |
S. Malathi, S. Narayana Kalkura, S. Balasubramanian. Applications of Multifunctional Nanomaterials. 2023; : 651 doi: 10.1016/B978-0-12-820557-0.00028-X
|
| 6 |
Elena Tabacchi, Cristina Nanni, Irene Bossert, Anna Margherita Maffione, Stefano Fanti. Nuclear Oncology. 2017; : 749 doi: 10.1007/978-3-319-26236-9_17
|
| 7 |
T Hamada, Y Nakai, H Yasunaga, H Isayama, H Matsui, N Takahara, T Sasaki, K Takagi, T Watanabe, H Yagioka, H Kogure, T Arizumi, N Yamamoto, Y Ito, K Hirano, T Tsujino, M Tada, K Koike. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. British Journal of Cancer 2014; 110(8): 1943 doi: 10.1038/bjc.2014.131
|
| 8 |
Man Kyu Shim, Jinhee Na, In Kyung Cho, Eun Hyang Jang, Jooho Park, Sangmin Lee, Jong-Ho Kim. Targeting of claudin-4 by Clostridium perfringens enterotoxin-conjugated polysialic acid nanoparticles for pancreatic cancer therapy. Journal of Controlled Release 2021; 331: 434 doi: 10.1016/j.jconrel.2021.01.031
|
| 9 |
Nirmal Goswami, Zhentao Luo, Xun Yuan, David Tai Leong, Jianping Xie. Engineering gold-based radiosensitizers for cancer radiotherapy. Materials Horizons 2017; 4(5): 817 doi: 10.1039/C7MH00451F
|
| 10 |
Lauren M. Rosati, Joseph M. Herman. Role of Stereotactic Body Radiotherapy in the Treatment of Elderly and Poor Performance Status Patients With Pancreatic Cancer. Journal of Oncology Practice 2017; 13(3): 157 doi: 10.1200/JOP.2016.020628
|
| 11 |
JUN GONG, RICHARD TULI, ARVIND SHINDE, ANDREW E. HENDIFAR. Meta-analyses of treatment standards for pancreatic cancer. Molecular and Clinical Oncology 2016; 4(3): 315 doi: 10.3892/mco.2015.716
|
| 12 |
Michael Stotz, Florian Eisner, Joanna Szkandera, Gudrun Absenger, Peter Kornprat, Carolin Lackner, Hellmut Samonigg, Armin Gerger, Martin Pichler. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series. Journal of Clinical Pathology 2013; 66(9): 753 doi: 10.1136/jclinpath-2012-201394
|
| 13 |
Chin-King Looi, Felicia Fei-Lei Chung, Chee-Onn Leong, Shew-Fung Wong, Rozita Rosli, Chun-Wai Mai. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. Journal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1153-8
|
| 14 |
Mehmet Salih Iyikesici. Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer. Complementary Medicine Research 2020; 27(1): 31 doi: 10.1159/000502135
|
| 15 |
Amit Dang, Surendar Chidirala, Prashanth Veeranki, B.N. Vallish. A Critical Overview of Systematic Reviews of Chemotherapy for Advanced and Locally Advanced Pancreatic Cancer using both AMSTAR2 and ROBIS as Quality Assessment Tools. Reviews on Recent Clinical Trials 2021; 16(2): 180 doi: 10.2174/1574887115666200902111510
|
| 16 |
Chen Liang, Si Shi, Qingcai Meng, Dingkong Liang, Shunrong Ji, Bo Zhang, Yi Qin, Jin Xu, Quanxing Ni, Xianjun Yu. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?. Cellular and Molecular Life Sciences 2018; 75(6): 1001 doi: 10.1007/s00018-017-2678-7
|
| 17 |
Hui Shan Liew, Chun-Wai Mai, Mohd Zulkefeli, Thiagarajan Madheswaran, Lik Voon Kiew, Nicolas Delsuc, May Lee Low. Recent Emergence of Rhenium(I) Tricarbonyl Complexes as Photosensitisers for Cancer Therapy. Molecules 2020; 25(18): 4176 doi: 10.3390/molecules25184176
|
| 18 |
Dannel Yeo, Nhi Huynh, John A. Beutler, Christopher Christophi, Arthur Shulkes, Graham S. Baldwin, Mehrdad Nikfarjam, Hong He. Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases. Cancer Letters 2014; 346(2): 264 doi: 10.1016/j.canlet.2014.01.001
|
| 19 |
Jiajia Pan, Nan Li, Alex Renn, Hu Zhu, Lu Chen, Min Shen, Matthew D. Hall, Min Qian, Ira Pastan, Mitchell Ho. GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling. Molecular Cancer Therapeutics 2022; 21(6): 960 doi: 10.1158/1535-7163.MCT-21-0778
|
| 20 |
Sho Yasuta, Tatsushi Kobayashi, Hidetoshi Aizawa, Shinichiro Takahashi, Masafumi Ikeda, Masaru Konishi, Motohiro Kojima, Hirofumi Kuno, Katsuhiko Uesaka, Soichiro Morinaga, Atsushi Miyamoto, Hirochika Toyama, Norihisa Takakura, Keishi Sugimachi, Wataru Takayama. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-07698-0
|
| 21 |
Sangjin Shin, Chan Mi Park, Hanbyeol Kwon, Kyung-Hun Lee. Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database. BMC Cancer 2016; 16(1) doi: 10.1186/s12885-016-2482-z
|
| 22 |
Geetanjali Arya, Manasi Das, Sanjeeb Kumar Sahoo. Evaluation of curcumin loaded chitosan/PEG blended PLGA nanoparticles for effective treatment of pancreatic cancer. Biomedicine & Pharmacotherapy 2018; 102: 555 doi: 10.1016/j.biopha.2018.03.101
|
| 23 |
Jian Li, Guohuang Hu, Fujiao Kong, Kemin Wu, Kun Song, Jianfeng He, Weijia Sun. Elevated STMN1 Expression Correlates with Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma. Pathology & Oncology Research 2015; 21(4): 1013 doi: 10.1007/s12253-015-9930-y
|
| 24 |
Jianwei Xu, Taiping Zhang, Tianxiao Wang, Lei You, Yupei Zhao. PIM kinases: an overview in tumors and recent advances in pancreatic cancer. Future Oncology 2014; 10(5): 865 doi: 10.2217/fon.13.229
|
| 25 |
Qin Li, Han Yan, Wenting Liu, Hongchao Zhen, Yifan Yang, Bangwei Cao, Jonathan R. Brody. Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE 2014; 9(8): e104346 doi: 10.1371/journal.pone.0104346
|
| 26 |
Wanwen Weng, Jiawei Hong, Kwabena G. Owusu-Ansah, Bingjie Chen, Shusen Zheng, Donghai Jiang. Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. Heliyon 2022; 8(12): e12064 doi: 10.1016/j.heliyon.2022.e12064
|
| 27 |
Chen Liang, Si Shi, Qingcai Meng, Dingkong Liang, Shunrong Ji, Bo Zhang, Yi Qin, Jin Xu, Quanxing Ni, Xianjun Yu. Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. Experimental & Molecular Medicine 2017; 49(12): e406 doi: 10.1038/emm.2017.255
|
| 28 |
Yi Zhou, Hongchun Liu, Ruyi Xue, Wenqing Tang, Shuncai Zhang. BH3 Mimetic ABT-199 Enhances the Sensitivity of Gemcitabine in Pancreatic Cancer in vitro and in vivo. Digestive Diseases and Sciences 2018; 63(12): 3367 doi: 10.1007/s10620-018-5253-7
|
| 29 |
Diego A.S. Toesca, Faisal Ahmed, Mehr Kashyap, J Richelcyn M. Baclay, Rie von Eyben, Erqi L. Pollom, Albert C. Koong, Daniel T. Chang. Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. Radiotherapy and Oncology 2020; 152: 63 doi: 10.1016/j.radonc.2020.07.053
|
| 30 |
Elena Tabacchi, Cristina Nanni, Irene Bossert, Anna Margherita Maffione, Stefano Fanti. Nuclear Oncology. 2017; : 1 doi: 10.1007/978-3-319-26067-9_17-2
|
| 31 |
Elena Tabacchi, Cristina Nanni, Irene Bossert, Anna Margherita Maffione, Stefano Fanti. Nuclear Oncology. 2016; : 1 doi: 10.1007/978-3-319-26067-9_17-1
|
| 32 |
Jing Zhou, Rongce Zhao, Feng Wen, Pengfei Zhang, Yifan Wu, Ruilei Tang, Hongdou Chen, Jian Zhang, Qiu Li. Cost-Effectiveness Analysis of Treatments for Metastatic Pancreatic Cancer Based on Prodige and MPACT Trials. Tumori Journal 2016; 102(3): 294 doi: 10.5301/tj.5000499
|
| 33 |
Yu-Zheng Xue, Tie-Long Wu, Yan-Min Wu, Ying-Yue Sheng, Zhe-Qiang Wei, Yu-Feng Lu, Li-Hua Yu, Jian-Ping Li, Zhao-Shen Li. DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma. Tumor Biology 2013; 34(5): 2857 doi: 10.1007/s13277-013-0846-4
|
| 34 |
Qiongli Su, Shengping Luo, Qiuhong Tan, Jun Deng, Sichun Zhou, Mei Peng, Ting Tao, Xiaoping Yang. The role of pyruvate kinase M2 in anticancer therapeutic treatments (Review). Oncology Letters 2019; doi: 10.3892/ol.2019.10948
|
| 35 |
Elisa Giovannetti, Elena Galvani. Targeted Therapies for Solid Tumors. Current Clinical Pathology 2015; : 9 doi: 10.1007/978-1-4939-2047-1_3
|
| 36 |
Xiu-Wei Zhang, Yu-Xiang Ma, Yang Sun, Yu-Bo Cao, Qin Li, Chong-An Xu. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. Targeted Oncology 2017; 12(3): 309 doi: 10.1007/s11523-017-0486-5
|
| 37 |
Dannel Yeo, Nhi Huynh, John A. Beutler, Graham S. Baldwin, Hong He, Mehrdad Nikfarjam. Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model. Journal of Investigative Surgery 2016; 29(6): 366 doi: 10.3109/08941939.2016.1160167
|
| 38 |
Lei Zhang, Martin H. Bluth, Amarpreet Bhalla. Molecular Diagnostics in the Neoplasms of the Pancreas, Liver, Gallbladder, and Extrahepatic Biliary Tract. Clinics in Laboratory Medicine 2018; 38(2): 367 doi: 10.1016/j.cll.2018.03.003
|
| 39 |
Abdur R. Shakir. A Near-Complete Response to Treatment with Gemcitabine plus nab®-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report. Case Reports in Oncology 2014; 7(3): 711 doi: 10.1159/000368346
|
| 40 |
Joon Oh Park, Do-Youn Oh, Chiun Hsu, Jen-Shi Chen, Li-Tzong Chen, Mauro Orlando, Jong Seok Kim, Ho Yeong Lim. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Research and Treatment 2015; 47(3): 343 doi: 10.4143/crt.2014.308
|
| 41 |
M Stotz, A Gerger, F Eisner, J Szkandera, H Loibner, A L Ress, P Kornprat, W A Zoughbi, F S Seggewies, C Lackner, T Stojakovic, H Samonigg, G Hoefler, M Pichler. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. British Journal of Cancer 2013; 109(2): 416 doi: 10.1038/bjc.2013.332
|
| 42 |
Jadd Shelton, Xiao Lu, Joseph A. Hollenbaugh, Jong Hyun Cho, Franck Amblard, Raymond F. Schinazi. Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. Chemical Reviews 2016; 116(23): 14379 doi: 10.1021/acs.chemrev.6b00209
|
| 43 |
Jianwei Xu, Tianxiao Wang, Zhe Cao, Hua Huang, Jian Li, Wenjing Liu, Shanglong Liu, Lei You, Li Zhou, Taiping Zhang, Yupei Zhao. MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Oncotarget 2014; 5(16): 6983 doi: 10.18632/oncotarget.2184
|
| 44 |
Daniel Ansari, Adam Gustafsson, Roland Andersson. Update on the management of pancreatic cancer: Surgery is not enough. World Journal of Gastroenterology 2015; 21(11): 3157-3165 doi: 10.3748/wjg.v21.i11.3157
|
| 45 |
Sridhar P. Susheela, Swaroop Revannasiddaiah, Ajaikumar Basavalingaiah. Stereotactic Hypofractionated Irradiation for Metastatic, Inoperable, and Recurrent Malignancies: A Modern Necessity, rather than a Luxury. Journal of Radiotherapy 2014; 2014: 1 doi: 10.1155/2014/489824
|
| 46 |
Laura Rosa Brunet, Thorsten Hagemann, Andrew Gaya, Satvinder Mudan, Aurelien Marabelle. Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?. OncoImmunology 2016; 5(4): e1112942 doi: 10.1080/2162402X.2015.1112942
|
| 47 |
Mjriam Capula, Macarena Perán, Geng Xu, Valentina Donati, Dicky Yee, Alessandro Gregori, Yehuda G. Assaraf, Elisa Giovannetti, Dongmei Deng. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. Drug Resistance Updates 2022; 64: 100864 doi: 10.1016/j.drup.2022.100864
|
| 48 |
Ruth Perets, Orli Greenberg, Talia Shentzer, Valeria Semenisty, Ron Epelbaum, Tova Bick, Shada Sarji, Ofer Ben-Izhak, Edmond Sabo, Dov Hershkovitz. Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring. The Oncologist 2018; 23(5): 566 doi: 10.1634/theoncologist.2017-0467
|
| 49 |
Kharat Aditi, Tan Chia Jie, Saeteaw Manit, Chhibber Anindit, Biskupiak Joseph, Veettil Sajesh K, Chaiyakunapruk Nathorn. Survival benefits and safety of chemotherapy regimens for pancreatic cancer: An umbrella review of meta-analyses of randomized controlled trials. Annals of Pancreatic Disorders and Treatment 2022; 4(1): 001 doi: 10.17352/apdt.000008
|
| 50 |
Jing Zhou, Rongce Zhao, Feng Wen, Pengfei Zhang, Ruilei Tang, Zedong Du, Xiaofeng He, Jian Zhang, Qiu Li. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study. Medical Oncology 2015; 32(4) doi: 10.1007/s12032-015-0580-4
|
| 51 |
Elena Tabacchi, Cristina Nanni, Irene Bossert, Anna Margherita Maffione, Stefano Fanti. Nuclear Oncology. 2017; : 1 doi: 10.1007/978-3-319-26067-9_17-3
|
| 52 |
Tingting Xu, Xiaoxuan Xu, Dongfang Liu, Di Chang, Siqi Li, Yeyao Sun, Jinbing Xie, Shenghong Ju. Visual Investigation of Tumor‐Promoting Fibronectin Potentiated by Obesity in Pancreatic Ductal Adenocarcinoma Using an MR/NIRF Dual‐Modality Dendrimer Nanoprobe. Advanced Healthcare Materials 2023; 12(25) doi: 10.1002/adhm.202300787
|
| 53 |
Miriam Bazan-Peregrino, Rocio Garcia-Carbonero, Berta Laquente, Rafael Álvarez, Ana Mato-Berciano, Marta Gimenez-Alejandre, Sara Morgado, Alba Rodríguez-García, Maria V Maliandi, M Carmen Riesco, Rafael Moreno, Mireia M Ginestà, Mercedes Perez-Carreras, Joan B Gornals, Susana Prados, Sofía Perea, Gabriel Capella, Ramon Alemany, Ramon Salazar, Emma Blasi, Carmen Blasco, Manel Cascallo, Manuel Hidalgo. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. Journal for ImmunoTherapy of Cancer 2021; 9(11): e003254 doi: 10.1136/jitc-2021-003254
|
| 54 |
Emrah Eraslan, Fatih Yildiz, Gulnihal Tufan, Ferit Aslan, Umut Demirci, Omur Berna Oksuzoglu. First line modified Folfirinox versus gemcitabine for advanced pancreatic cancer: A single institution retrospective experience. Journal of Oncological Sciences 2019; 5(1): 1 doi: 10.1016/j.jons.2019.03.002
|
| 55 |
Yanxun Li, Jinjin Sun, Zhijia Jiang, Linqiang Zhang, Geng Liu. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia. Journal of Chemotherapy 2015; 27(4): 227 doi: 10.1179/1973947815Y.0000000013
|
| 56 |
Sophie Schneitler, Patric Kröpil, Jasmin Riemer, Gerald Antoch, Wolfram Trudo Knoefel, Dieter Häussinger, Dirk Graf. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection. World Journal of Gastroenterology 2015; 21(20): 6384-6390 doi: 10.3748/wjg.v21.i20.6384
|